Law firms Skadden, Freshfields and Davis Polk take the lead as blockbuster Pfizer/AstraZeneca deal gears up again Jaishree Kalia · 28 April 2014 · 2 min read Corporate and M&A Davis Polk Freshfields Skadden, Arps, Slate, Meagher & Flom Skadden, Arps, Slate, Meagher & Flom, Freshfields Bruckhaus Deringer and Davis Polk & Wardwell have all landed lead roles advising Pfizer and AstraZeneca as talks over a potential $100bn merger resurface.Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact [email protected] Related ContentMore in this category‘One engine, configured a thousand different ways’ – is Claude for Legal the next big shift in legal tech?Law firmsTom Cox28 May 2026Elite US firms in the cockpit as SpaceX files for landmark IPOLaw firmsKate Peacock21 May 2026‘They ripped the Band-Aid off’ – why Wachtell and other elite firms are tearing up partner payLaw firmsWill Lewallen19 May 2026‘It’s harder than it looks’ – inside the $1.65bn elite Indian cricket sale with the Macfarlanes partners behind the dealLaw firmsTom Cox29 May 2026‘We want to be there for the issues that keep our clients up at night’ – De Brauw co-head talks strategyLaw firmsTom Cox29 May 2026Latham hires three-partner City corporate team from Morrison FoersterLaw firmsWill Lewallen28 May 2026Revolving doors: Simpson Thacher, Latham, Sidley lead New Year London movesLaw firmsAnna Huntley9 Jan 2025Five partners vie to succeed Hoyland as Simmons managing partnerLaw firmsTom Cox7 Jan 2025‘Seize every opportunity’ – Paul Hastings partner Reena Gogna on City law, Suits and poetryLaw firmsAnna Huntley7 Jan 2025